Mitchell S. Levine - Mar 15, 2022 Form 4 Insider Report for Oncocyte Corp (OCX)

Role
Chief Financial Officer
Signature
/s/ Mitch Levine
Stock symbol
OCX
Transactions as of
Mar 15, 2022
Transactions value $
$0
Form type
4
Date filed
3/17/2022, 09:21 PM

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction OCX Option to Purchase Common Stock Award $0 +87.5K $0.00 87.5K Mar 15, 2022 Common Stock 87.5K $1.15 Direct F1
transaction OCX Option to Purchase Common Stock Award $0 +87.5K $0.00 87.5K Mar 15, 2022 Common Stock 87.5K $1.15 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the options will become exercisable after one year of continuous service from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to continuous service through the applicable vesting date.
F2 Options vest subject to the Issuer's achievement of pre-defined product development, regulatory and financial goals in 2022. 100% of the options will vest on December 31, 2023, if such pre-defined goals have been achieved in 2022, subject to continuous service through the vesting date.